| Research | IND-Enabling | Phase 1 | Phase 1/2 | Phase 3 | Regulatory Submission |
Approved |
|---|---|---|---|---|---|---|
Ripretinib
KIT Inhibitor
-
GIST ≥4ᵗʰ Line (INVICTUS Study)⁽¹⁾
-
GIST 2nd Line KIT Exon 11 + 17/18 (INSIGHT Phase 3 Study)⁽²⁾
DCC-3116
ULK Inhibitor
-
+ Trametinib (MEK Inhibitor)
-
+ Binimetinib (MEK Inhibitor)
-
+ Sotorasib (KRASᴳ¹²ᶜ Inhibitor)
-
+ Encorafenib (BRAF Inhibitor) and Cetuximab (EGFR Inhibitor)
Additional Programs
-
Undisclosed Program #1
-
Undisclosed Program #2
-
VPS34 Program (Solid Tumors)⁽³⁾
Updated as of January 2023; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) Without an exon 9, 13, or 14 mutation; (3) Agreement with Sprint Bioscience for exclusive in-license worldwide rights to a research-stage program targeting VPS34.